Mr. Young is an analytical and results driven life sciences executive who has successfully managed public and private companies through product development, international growth, commercialization and M&A transactions. He has served as a Director and Chief Executive Officer for public companies for the past 20 years where he has created significant shareholder value, built integrated scientific, manufacturing and commercial operations, directed successful M&A transactions and was responsible for generating more the $900M through acquisitions and equity financings. Mr. Young started his management career in the biopharmaceutical industry at Genentech Inc. where he was responsible for their cardiovascular and endocrine product launches sales and marketing.
Baxter is a seasoned life sciences executive whose experience spans the continuum from preclinical drug research and manufacturing to product launch, commercialization and operations management and finance. In his 20+ years in the pharmaceutical industry he has served as a director and C-Level executive and director of multiple public and private companies, including Insmed (INSM), Asertio (ASRT), and Neurogastrx. He has a B.S. in Biology from Hampden-Sydney College and an MBA from The Mason School of Business at the College of William and Mary.
Mathew has over 15 years of experience as a finance executive. Mathew currently serves as president of Manning Lee Management Ltd., a management consulting firm providing CFO services to publicly traded companies. Mathew specializes in providing M&A, accounting, management, securities regulatory compliance, and corporate secretarial services to companies listed on the TSX-V, CSE, and OTC. Mathew is a CPA Charterholder and earned a B.Comm from the University of British Columbia.
Prior to leading science and technology efforts at LOBE, Dariani was President of Focus Pharmaceuticals, Inc., where he managed the development and approval of drug products, achieving one FDA approval and bringing another to the clinical evaluation stage, then successfully negotiated the sale of the company in February 2003. Prior to Focus, Maghsoud was Vice President of the chiral pharmaceutical business unit at Celgene Corporation. During his twelve years at Celgene, he was responsible for the successful development and FDA approval of the chirally pure versions of Ritalin, which are currently marketed by Novartis under the Focalin and Focalin XR trade names.
Dr. Sancilio is a serial entrepreneur in the healthcare field and is currently a principle of Clearway Global, Inc., a pharmaceutical development advisory service. He has served as an executive and director of both private and public companies including Applied Analytical Industries, Inc., aaiPharma, Inc., Endeavor Pharmaceutical Company, Aesgen, Inc., Sancilio & Company, Alpha Cognition, Inc., TrippBio, Inc., Omega Blu, LLC and Nation’s Bank of North Carolina. He was appointed as a Research Professor at Florida Atlantic University and was an adjunct professor of chemistry at the University of North Carolina. Dr. Sancilio received his Master of Science and Doctorate degrees from Rutgers, The State University of New Jersey.